Sanofi/Alnylam’s haemophilia drug hits another safety speed-bumpSanofi’s attempt to take on Roche with a ground-breaking approach to treating haemophilia has hit a setback after Share XSanofi/Alnylam’s haemophilia drug hits another safety speed-bumphttps://pharmaphorum.com/news/sanofi-alnylans-haemophilia-drug-hits-another-safety-speed-bump/
Novo Nordisk builds in haemophilia with Bluebird Bio gene editing dealAnxious not to be left behind in the haemophilia market, Novo Nordisk has forged an alliance with Bluebird Share XNovo Nordisk builds in haemophilia with Bluebird Bio gene editing dealhttps://pharmaphorum.com/news/novo-nordisk-builds-in-haemophilia-with-bluebird-bio-gene-editing-deal/
NHS reimburses Roche’s Hemlibra in new group of haemophilia patientsNHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, Share XNHS reimburses Roche’s Hemlibra in new group of haemophilia patientshttps://pharmaphorum.com/news/roche-hemlibra-haemophilia/
Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialCatalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market Share XCatalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialhttps://pharmaphorum.com/news/catalysts-rival-to-novoseven-hits-the-mark-in-phase-2-haemophilia-trial/
BioMarin seeks haemophilia gene therapy approval after promising dataBioMarin is set to file for approval for its haemophilia gene therapy valoctocogene roxaparvovec, after it achieved pre-specified Share XBioMarin seeks haemophilia gene therapy approval after promising datahttps://pharmaphorum.com/news/biomarin-seeks-haemophilia-gene-therapy-approval-after-promising-data/
The unmet needs of bleeding disorder patientsAhead of eyeforpharma Philadelphia 2019, we talk to speaker and haemophilia advocate Michelle Rice about the changing landscape Share XThe unmet needs of bleeding disorder patientshttps://pharmaphorum.com/views-analysis-patients/the-unmet-needs-of-bleeding-disorder-patients/
EU expands use of Roche’s new haemophilia A drugThe European Commission has approved Roche haemophilia A drug Hemlibra for patients without factor VIII inhibitors, expanding the Share XEU expands use of Roche’s new haemophilia A drughttps://pharmaphorum.com/news/eu-expands-use-of-roches-new-haemophilia-a-drug/
Gene therapy firm BioMarin stages haemophilia musicalBioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression Share XGene therapy firm BioMarin stages haemophilia musicalhttps://pharmaphorum.com/news/gene-therapy-firm-biomarin-stages-haemophilia-musical/
How pharma can boost engagement by embracing support networksConnecting with patients has become a central plank in the pharma marketing playbook, but should companies be looking Share XHow pharma can boost engagement by embracing support networkshttps://pharmaphorum.com/patients/insights-patients/how-pharma-can-boost-engagement-by-embracing-support-networks/
